Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.

Zhang Z, Ding Q, Liu JJ, Zhang J, Jiang N, Chu XJ, Bartkovitz D, Luk KC, Janson C, Tovar C, Filipovic ZM, Higgins B, Glenn K, Packman K, Vassilev LT, Graves B.

Bioorg Med Chem. 2014 Aug 1;22(15):4001-9. doi: 10.1016/j.bmc.2014.05.072.

PMID:
24997575
2.
3.

Small-molecule MDM2-p53 inhibitors: recent advances.

Zhang B, Golding BT, Hardcastle IR.

Future Med Chem. 2015;7(5):631-45. doi: 10.4155/fmc.15.13. Review.

PMID:
25921402
4.

MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.

Tovar C, Graves B, Packman K, Filipovic Z, Higgins B, Xia M, Tardell C, Garrido R, Lee E, Kolinsky K, To KH, Linn M, Podlaski F, Wovkulich P, Vu B, Vassilev LT.

Cancer Res. 2013 Apr 15;73(8):2587-97. doi: 10.1158/0008-5472.CAN-12-2807.

5.

Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.

Ding Q, Zhang Z, Liu JJ, Jiang N, Zhang J, Ross TM, Chu XJ, Bartkovitz D, Podlaski F, Janson C, Tovar C, Filipovic ZM, Higgins B, Glenn K, Packman K, Vassilev LT, Graves B.

J Med Chem. 2013 Jul 25;56(14):5979-83. doi: 10.1021/jm400487c.

PMID:
23808545
6.

A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice.

Zhao Y, Yu S, Sun W, Liu L, Lu J, McEachern D, Shargary S, Bernard D, Li X, Zhao T, Zou P, Sun D, Wang S.

J Med Chem. 2013 Jul 11;56(13):5553-61. doi: 10.1021/jm4005708.

7.

Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.

Hai J, Sakashita S, Allo G, Ludkovski O, Ng C, Shepherd FA, Tsao MS.

J Thorac Oncol. 2015 Aug;10(8):1172-80. doi: 10.1097/JTO.0000000000000584.

8.

Identification of High Affinity Non-Peptidic Small Molecule Inhibitors of MDM2-p53 Interactions through Structure-Based Virtual Screening Strategies.

Bandaru S, Ponnala D, Lakkaraju C, Bhukya CK, Shaheen U, Nayarisseri A.

Asian Pac J Cancer Prev. 2015;16(9):3759-65.

9.

Computational analysis of spiro-oxindole inhibitors of the MDM2-p53 interaction: insights and selection of novel inhibitors.

Huang W, Cai L, Chen C, Xie X, Zhao Q, Zhao X, Zhou HY, Han B, Peng C.

J Biomol Struct Dyn. 2016;34(2):341-51. doi: 10.1080/07391102.2015.1031178.

PMID:
25808617
10.

MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.

Canner JA, Sobo M, Ball S, Hutzen B, DeAngelis S, Willis W, Studebaker AW, Ding K, Wang S, Yang D, Lin J.

Br J Cancer. 2009 Sep 1;101(5):774-81. doi: 10.1038/sj.bjc.6605199.

11.

Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer.

Shangary S, Ding K, Qiu S, Nikolovska-Coleska Z, Bauer JA, Liu M, Wang G, Lu Y, McEachern D, Bernard D, Bradford CR, Carey TE, Wang S.

Mol Cancer Ther. 2008 Jun;7(6):1533-42. doi: 10.1158/1535-7163.MCT-08-0140.

12.

Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors.

Hu C, Li X, Wang W, Zhang L, Tao L, Dong X, Sheng R, Yang B, Hu Y.

Bioorg Med Chem. 2011 Sep 15;19(18):5454-61. doi: 10.1016/j.bmc.2011.07.050.

PMID:
21855354
13.

Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.

Yu S, Qin D, Shangary S, Chen J, Wang G, Ding K, McEachern D, Qiu S, Nikolovska-Coleska Z, Miller R, Kang S, Yang D, Wang S.

J Med Chem. 2009 Dec 24;52(24):7970-3. doi: 10.1021/jm901400z.

14.

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition.

Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S, Nikolovska-Coleska Z, Ding K, Wang G, Chen J, Bernard D, Zhang J, Lu Y, Gu Q, Shah RB, Pienta KJ, Ling X, Kang S, Guo M, Sun Y, Yang D, Wang S.

Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3933-8. doi: 10.1073/pnas.0708917105.

15.

Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma.

Chen L, Zhao Y, Halliday GC, Berry P, Rousseau RF, Middleton SA, Nichols GL, Del Bello F, Piergentili A, Newell DR, Lunec J, Tweddle DA.

Br J Cancer. 2014 Aug 12;111(4):716-25. doi: 10.1038/bjc.2014.325.

16.

Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.

Zhuang C, Miao Z, Zhu L, Dong G, Guo Z, Wang S, Zhang Y, Wu Y, Yao J, Sheng C, Zhang W.

J Med Chem. 2012 Nov 26;55(22):9630-42. doi: 10.1021/jm300969t.

PMID:
23046248
17.

Targeting MDM2-p53 interaction for cancer therapy: are we there yet?

Nag S, Zhang X, Srivenugopal KS, Wang MH, Wang W, Zhang R.

Curr Med Chem. 2014;21(5):553-74. Review.

PMID:
24180275
18.

FOLICation: engineering approved drugs as potential p53-MDM2 interaction inhibitors for cancer therapy.

Patil SP.

Med Hypotheses. 2013 Dec;81(6):1104-7. doi: 10.1016/j.mehy.2013.10.014.

PMID:
24210632
19.

Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.

Ding K, Lu Y, Nikolovska-Coleska Z, Wang G, Qiu S, Shangary S, Gao W, Qin D, Stuckey J, Krajewski K, Roller PP, Wang S.

J Med Chem. 2006 Jun 15;49(12):3432-5.

PMID:
16759082
20.

Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors.

Zhao Y, Liu L, Sun W, Lu J, McEachern D, Li X, Yu S, Bernard D, Ochsenbein P, Ferey V, Carry JC, Deschamps JR, Sun D, Wang S.

J Am Chem Soc. 2013 May 15;135(19):7223-34. doi: 10.1021/ja3125417.

Items per page

Supplemental Content

Support Center